{"title":"Renin Angiotensin System and Coronavirus Disease 2019 (COVID-19): An updated review","authors":"Rolando S Vela Vásquez","doi":"10.7243/2052-4358-8-2","DOIUrl":null,"url":null,"abstract":"Abnormal Renin-Angiotensin System (RAS) activation has a pivotal role in pathogenesis of cardiovascular or metabolic diseases, known risk factors for poor outcomes in COVID-19. An additional tissue RAS imbalance trough interaction of ‘severe acute respiratory syndrome coronavirus 2’ (SARS-CoV-2) with angiotensin-converting enzyme 2 (ACE-2) seems to play a role in pathogenesis of COVID-19. This interaction has raised some questions about safety of RAS-inhibitors use in COVID-19 patients. On the other hand, potential benefits of RAS-inhibitors use have been suggested. This article presents a brief updated review of renin-angiotensin system (RAS) focusing on interaction with SARS-CoV-2 infection, potential risks or benefits of RAS-inhibitors use, and RAS-related therapeutic targets in COVID-19.","PeriodicalId":84943,"journal":{"name":"IRCS medical science: Cardiovascular system","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IRCS medical science: Cardiovascular system","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7243/2052-4358-8-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Abnormal Renin-Angiotensin System (RAS) activation has a pivotal role in pathogenesis of cardiovascular or metabolic diseases, known risk factors for poor outcomes in COVID-19. An additional tissue RAS imbalance trough interaction of ‘severe acute respiratory syndrome coronavirus 2’ (SARS-CoV-2) with angiotensin-converting enzyme 2 (ACE-2) seems to play a role in pathogenesis of COVID-19. This interaction has raised some questions about safety of RAS-inhibitors use in COVID-19 patients. On the other hand, potential benefits of RAS-inhibitors use have been suggested. This article presents a brief updated review of renin-angiotensin system (RAS) focusing on interaction with SARS-CoV-2 infection, potential risks or benefits of RAS-inhibitors use, and RAS-related therapeutic targets in COVID-19.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
